Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-0102 versus placebo in MELAS
NL-OMON60219Phase 2Completed
- Sponsor
- Thiogenesis Therapeutics
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mitochondrial encephalomyopathies comparing TTI-0102 with Placebo (2 arms). Primary endpoints: Change in functional capacity by 12-minute walk test and Safety and tolerability. Started Mar 2025; status: completed.
02
Drugs
cysteamine-pantetheine disulfide
03
Conditions
mitochondrial encephalomyopathies
Beyond the preview
Go deeper on NL-OMON60219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60219.